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1. Introduction 
Urinary Tract Infections (UTIs) account for nearly 8 million physician visits and 1.5 million 
visits to emergency rooms annually in the United States (Foxman, 2003; Litwin et al., 2005; 
Stamm and Hooton, 1993). It is the second most common infection of any organ and is one 
of the most common infections in humans (Tabiban et al., 2008). UTIs account for a total 
annual cost of more than $ 3.5 billion in the United States (Litwin et al., 2005). UTI refers to 
the presence of clinical signs and symptoms arising from the genitourinary tract associated 
with the presence of one or more microorganisms (Guay, 2009). UTIs are usually localized to 
the bladder, kidneys or prostate. The term UTI in this chapter refers to infections of the 
lower urinary tract that involve the bladder and urethra. Escherichia coli is the predominant 
uropathogen responsible for roughly 80% of all UTI cases, followed by Staphylococcus, 
Klebsiella, Enterobacter, Proteus and Enterococci species (Ronald, 2003). 
There are several approaches to the treatment and management of UTIs. Accurate 
classification of cases is the foremost and critical step in the clinical management of UTIs. 
UTIs may be primarily distinguished between the two anatomic locations of the infection, 
namely upper and lower tract infections. In majority of cases, the infection is associated with 
the lower part of the tract (Najar et al., 2009). Additionally, the infection may also be 
classified as complicated and uncomplicated based on the level of tissue involvement. 
Uncomplicated infections engross an episode of cysto-urethritis associated with bacterial 
colonization of the ureteral and bladder mucosa. Complicated infections involve 
pyelonephritis or prostitis and often occur as a result of obstruction or instrumentation in 
the tract (Huland and Busch, 1984; Najar et al., 2009). UTIs may also be classified as 
recurrent infection, reinfection or relapse (Najar et al., 2009). Reinfection is recurring 
infection due to a different microorganism that is usually drug susceptible, whereas relapse 
is a return of infection due to the same microorganism which is drug resistant. A relapse 
implies that there has been a failure to eradicate the infection (Cattell, 1973).  
Traditionally, the treatment of UTIs consists of antimicrobial therapy administered in a 
regimen appropriate to the clinical situation, freqently administered temporally either as a 
prophylactic to reduce the risk of UTI or as a therapeutic approach. Several antibiotics such 
as penicillins, sulfanilamide, nitrofurantoin and cephalexin have been used in therapy 
(Nicolle, 2002). The customary UTI treatment involves a short course of antimicrobials such 
as a 3-day regimen of trimethorpim-sulfamethoxazole combination (Nickel, 2005a). This 
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initial therapy is based on knowledge of the predominant pathogens and their antimicrobial 
susceptibility (Perez-Lopez et al., 2009). Besides the therapeutic approach, preventive 
treatment with antibiotics are also administered to susceptible populations, including the 
elderly, children and women with recurrent UTIs. However, one major drawback to the use 
of antibiotics is the potential for development of antibiotic resistance among uropathogens 
(Head et al., 2008). The increasing prevalence of antibiotic resistant bacteria, escalating costs 
of antibiotic therapy and unsatisfactory therapeutic alternatives in recurrent UTIs have 
stimulated an interest in novel, non-antibiotic based methods for preventing and controlling 
UTIs (Vaughan, 2007; Smith et al., 2006).  
2. Alternative treatment options 
UTIs have been a common illness in humans long before bacteria were recognized as the 
causative agents. Initial therapy for UTIs was primarily the use of herbal treatments to 
ameliorate urinary symptoms, as recorded in the Ebers papyrus from ancient Egypt (Nickel, 
2005b).  The early 19th century provided detailed descriptions of UTIs with treatment that 
included hospitalization, bed rest, attention to diet, plastics, narcotics, herbal enemas, 
douches and surgery for stones, abscess and retention (Nickel, 2005b). However, with the 
advent of modern medicine, the use of select antibacterial agents and antibiotics for the 
treatment of UTIs was put into practice. Although the effectiveness of antibiotics was 
validated in clinical practice, the continued use of select agents in the prophylaxis and 
therapy of UTIs led to the emergence of antibiotic resistant uropathogens (Nickel, 2005c). 
This triggered an interest in the application of alternative, non-antibiotic approaches for 
preventing and controlling UTIs. This chapter discusses the various alternative approaches 
that are currently available and are being evaluated to control UTIs. These include the use of 
plant derived antimicrobials, probiotics, and vaccines targeting  specific proteins in 
uropathogens. 
2.1 Plant derived antimicrobials 
Historically, plants have served as a basis for development of novel drugs, thereby 
contributing to human health and well-being. A variety of plant-derived polyphenols serve 
as dietary constituents as well as active components in a number of herbal and traditional 
medicines (Wollenweber, 1988).  In excess of 5000 plant polyphenols have been identified, 
and several of them exhibit a wide spectrum of biological effects, including anti-
inflammatory, antimicrobial, and anti-carcinogenic properties (Beretz et al., 1978).  Several 
of them have been also used in the treatment and control of UTIs. These include cranberry, 
blueberry, berberine, bearberry, cinnamon and other herbs. Since several plant 
antimicrobials contain different functional groups in their structure, their antimicrobial 
activity is attributed to multiple mechanisms (Burt, 2004). Therefore, unlike antibiotics, the 
potential for bacteria to develop resistance to plant antimicrobials is relatively smaller 
(Ohno et al., 2003).  
2.1.1 Vaccinium macrocarpon (Cranberry) 
A significant body of literature exists on the positive effects of dietary intake of berry fruits 
on human health, performance and disease (Seeram, 2008). The ripe fruit of the cranberry is 
the part of the plant that is most commonly used for medicinal purposes. Cranberries are 
composed of 80-88% water and approximately 10% carbohydrates. Flavanoids, 
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anthocyanins, catechin, triterpenoids, organic acids and ascorbic acid are the other 
constituents that make up the rest of the 10% (Siciliano, 1996; Raz et al., 2004). Cranberry 
products such as the juice and tablets have been used as an alternative medicine to prevent 
UTIs in humans for decades.  
Clinical and epidemiological studies support the use of cranberry in maintaining a healthy 
urinary tract (Perez-Lopez et al., 2009). The first controlled clinical trial demonstrating the 
use of cranberry juice in reducing the presence of bacteria in urine was conducted by Avorn 
and others (1994). This study included 192 participants, where baseline urine samples, 
followed by monthly samples were collected over a six month period, during which 
participants regularly consumed 300 ml of cranberry juice daily. The results of this study 
revealed that bacteriuria and pyuria occurred in 28% of the placebo group in comparison to 
only 14% in the cranberry juice group.  Following this initial study, there have been several 
other investigations that demonstrated the antimicrobial property of cranberries against 
uropathogens. Although several studies have tested the antimicrobial effect of cranberries 
against multiple uropathogens, it was found to be most effective against uropathogenic E. 
coli (UPEC). 
Di Martino et al (2005) investigated the effect of cranberry juice on UPEC biofilm population 
in a small group of human subjects. Similarly, Bailey et al (2007) conducted a study in 
women with recurrent UTI to evaluate the effects of a daily dose of concentrated cranberry 
extracts for a period of 12 weeks. In another study conducted by Bohbot (2007), a 
comparison was made between the use of proanthocyanidins (PAC) and cranberry total 
components. The results of the study demonstrated that components other than PAC also 
contribute to the UTI preventive effect of cranberries.  
No definitive mechanism of action has been identified to explain the antimicrobial effect of 
cranberries against uropathogens. The initial hypothesis suggested that cranberry acidity 
produces the antibacterial effect in the body, but it was later disproved (Blatherwick and 
Long, 1923). Cranberries exert anti-adhesive effects on certain uropathogens (Ohnishi et al., 
2006) and this effect is specific to certain components of cranberry (Ofek et al., 1991). 
Cranberries contain three different flavonoids (flavonols, anthocyanins and PAC), catechins, 
hydroxycinnamic and other phenolic acids and triterpenoids. The anthocyanins are 
absorbed in the human circulatory system and transported without any chemical change to 
the urine (Perez-Lopez et al., 2009). Cranberry products do not inhibit bacterial growth, but 
inhibit bacterial adherence to uroepithelial cells, thereby reducing the development of UTI. 
The anti-adhesive effects of p-fimbriated UPEC to uroepithelial cells are related to A-linked 
PAC as compared with lack of anti-adhesion activities of B-linked PAC from grape, apple 
juice, green tea and chocolate (Howell et al., 2005). The A-type PAC in cranberries enhance 
the anti-adhesive effects in vitro and in urine. PAC binds to lipopolysaccharide in gram 
negative bacteria. When E. coli was grown in the presence of cranberry components, the 
bacterial morphology changed to a more spherical cell-like form. These changes cause them 
to be repelled by the human cells (Liu et al., 2006).  
Lavigne et al (2008) investigated the effect of cranberry capsules on bacterial adherence to 
urinary tract. Participants who consumed cranberry capsules showed a significant dose-
dependent reduction in bacterial adherence to urinary epithelial cells compared to placebo. 
Another potential mechanism of action of cranberry against UPEC is the non-enzymatic 
generation of nitric oxide under mildly acidic conditions (MacMiking et al., 1997). Nitric 
oxide possesses potent antimicrobial activities that are both time and dose-dependent. 
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Although, cranberry has demonstrated potential against UTIs, dose administration 
recommendations of cranberry products have been poorly defined (Perez-Lopez et al., 2009). 
Available products include sweetened cranberry juice (OceanSpray®), which is 25% pure 
juice. Recommended doses vary from 4 to 32 oz/day. Recommended doses of the dried 
concentrated juice range from 600 to greater than 1200 mg/day (Ross, 2006; Lynch, 2004).  
Cranberry has undergone extensive evaluation in the management of UTIs. Currently, there 
is no evidence that cranberry can be used to treat UTIs. Hence, the focus has been on its use 
as a prophylactic agent in the prevention of UTIs (Guay, 2009). The consumption of 
cranberry juice can help to prevent the adhesion of UPEC to the uroepithelium and thereby 
help reduce the incidence of UTIs. With rising concerns of antibiotic resistance among 
UPEC, cranberry could serve as an effective alternative in controlling UTIs. 
2.1.2 Vaccinium myrtillus (Bilberry; Blueberry) 
Blueberry extracts possess constituents similar to that found in cranberry extracts. Although 
extensive studies have not been performed on the antimicrobial effects of blueberry extracts, 
evidence indicates that blueberry extracts possess similar anti-adhesive effects against 
uropathogenic bacteria (Head, 2008). When compared to other fruit extracts such as guava, 
mango, orange, grapefruit or pineapple, blueberry constituents were reported to bind to the 
same uroepithelial cells where bacteria attach (Ofek et al., 1991; 1996). These studies 
demonstrated that the constituents in blueberry extracts like those in cranberry inhibited 
UPEC from adhering to the uroepithelial cells using the mannose-resistant adhesins. 
Similarly, Weiss et al (2002), compared the effect of cranberry, mango, melon, peach, plum 
and raspberry extracts on the ability of oral bacteria to aggregate and colonize the oral 
mucosa. It was found that only members of the Vaccinium genus were able to inhibit the 
bacterial aggregation. Cranberry extract was found to be most effective followed by   
blueberry, thus suggesting that blueberry may also serve as an alternative to the use of 
antibiotics in preventing UTIs. 
2.1.3 Berberine 
Berberine is an alkaloid present in many plants, including Hydrastis canadensis (goldenseal), 
Coptis chinensis (Coptis or goldenthread), Berberis aquifolium (Oregon grape), Berberis vulgaris 
(barberry) and Berberis aristata (tree turmeric). Berberine is present in the root, rhizome, and 
stem bark of the plants. Berberine extracts have been shown to be effective against a variety 
of organisms, including bacteria, viruses, fungi, protozoans, helminthes and Chlamydia 
(Head, 2008). Research using berberine demonstrated its inhibitory effect on the growth of 
several bacterial pathogens such as  Staphylococcus aureus, Pseudomonas aeruginosa, , E. coli, 
and Bacillus subtilis (Cernakova and Kostalova, 2002). Supporting this finding, another study 
revealed that alkaloids from Hydrastis sp. possessed antibacterial activity against E. coli, S. 
aureus and P. aeruginosa (Scazzocchio et al., 2001). The antimicrobial effect of the ingredient 
alkaloids in the order of potency was  berberine > coptisine > palmatine (Yan et al., 2008). 
Although the mechanisms behind antimicrobial property of berbine is not completely 
understood,  it was reported to target the FtsZ protein involved in the first stage of bacterial 
cell division (Domadia et al., 2008). 
In controlling UTIs, the antibacterial effect of berberine was attributed to its ability to inhibit 
bacterial adhesion to uroepithelial cells. Sun et al (1988a) demonstrated that growth of 
clinical isolates of E. coli in the presence of berberine sulfate completely inhibited fimbrial 
www.intechopen.com
 
Natural Approaches for Controlling Urinary Tract Infections 231 
synthesis. Likewise, berberine sulfate was found to inhibit the capacity of Streptococcus 
pyogenes to adhere to host cells (Sun et al., 1988b). Since E. coli infection in the urinary tract 
has been attributed to the  migration of the pathogen from the gut, a reduction of E. coli load 
in the gut can indirectly reduce UTIs (Rabbani et al., 1987). In this context, berberine has 
been demonstrated to reduce E. coli induced diarrhea in human and animal subjects through 
its anti-secretory effects, thereby reducing the likelihood of bacterial migration into the 
urinary tract (Sach and Froehlich, 1982).  
2.1.4 Arctostaphylos uva ursi (Bearberry) 
This is another fruit commonly used for its antimicrobial property in controlling  UTIs 
(Head, 2008). The active antimicrobial ingredient in bearberry is an aglycone hydroquinone 
which is released in alkaline urine (Uva ursi, 2004). A study conducted by Schindler et al 
(2002) involving human subjects who consumed a dried leaf extract of uva ursi showed that  
64.8% of arbutin consumed in tablet form and 66.7% of arbutin ingested in aqueous solution 
were released in the urine. This significant level of the fruit extract in urine was attributed to 
its antimicrobial effect. Frohne (1970) and Kedzia et al (1975) conducted clinical studies with 
human subjects in which urine from patients given extracts of uva ursi or isolated arbutin 
was evaluated. The urine from the treatment group demonstrated significant antimicrobial 
activity against E. coli, P. mirabilis, P. aeruginosa, S. aureus and 70 other urinary bacteria. 
Frohne (1970) also demonstrated that the crude extract of uva ursi was more effective 
against bacteria than  arbutin by itself. The one and only clinical study to investigate the 
effect of uva ursi in controlling UTIs was conducted by Larsson et al (1993). This study 
involved 57 women with chronic UTIs who were assigned to uva ursi extract or placebo for 
a period of one month and subsequently followed for a year. A statistically significant 
reduction in the incidence of UTIs was noted in the treatment group when compared to that 
in the placebo group, thereby demonstrating its efficacy as an antimicrobial against UTIs.  
The antimicrobial activity of uva ursi was attributed to its ability to change microbial cell 
surface characteristics. Supporting this, a study by Turi et al (1997) demonstrated that 
growth of clinical isolates of E. coli in the presence of uva ursi extracts increased the 
microbial cell surface hydrophobicity, thereby decreasing their ability to adhere to host cells. 
Additionally, uva ursi has diuretic and anti-inflammatory effects that indirectly aid in its 
use as an antimicrobial to control UTIs (Beaux et al., 1999; Kubo et al., 1990). 
2.1.5 Trans-cinnamaldehyde 
Trans-cinnamaldehyde (TC) is a major component of the bark extract of cinnamon (Adams 
et al., 2004). It is a generally recognized as safe (GRAS) molecule approved for use in foods 
by the Food and Drug Administration (FDA). The U. S. Flavoring Extract Manufacturers’ 
Association reported that TC has a wide margin of safety between conservative estimates of 
intake and no observed adverse effect levels, from sub-chronic and chronic studies (Adams 
et al., 2004). The report also indicated no genotoxic or mutagenic effects due to TC. The 
antibacterial activity of TC against Clostridium botulinum (Bowles and Miller, 1993), S. aureus 
(Bowles et al., 1995), E. coli O157:H7 and Salmonella Typhimurium (Helander et al., 1998) has 
been previously reported. Although, cinnamon or cinnamon oil has been used for ages in 
the treatment of UTIs,  no scientific study was undertaken to investigate its antimicrobial 
efficacy against uropathogens.  Amalaradjou et al (2010) were the first to demonstrate the 
ability of trans-cinnamaldehyde to inactivate and inhibit UPEC biofilm formation on urinary 
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catheters. A follow up study conducted by the same group (Amalaradjou et al., 2011) 
indicated that trans-cinnamaldehyde inhibited the adhesion and invasion of uroepithelial 
cells by UPEC by downregulating major virulence genes in the pathogen. These results 
indicate the potential use of trans-cinnamaldehyde as an antimicrobial for controlling UTIs.  
The antimicrobial effect of TC could be attributed to multiple mechanisms. A critical 
property of essential oils or their components, including TC is their hydrophobicity, which 
helps them to target the lipid-containing bacterial cell membrane and mitochondria 
(Sikkema et al., 1994). This makes these membranes more permeable, leading to leakage of 
ions and other cell contents. In addition to the effect on cell membranes, TC is also believed 
to kill bacteria by inhibiting energy generation and glucose uptake (Gill and Holey, 2006). 
Yet another mechanism by which cinnamon oil and its components kill microorganisms is 
by their inhibitory effect on enzymes such as amino acid decarboxylases (Wendakoon and 
Sakaguchi, 1995). It is also known that plant essential oils and their components, including 
that from cinnamon are capable of inhibiting the production of virulence factors, and 
modulating bacterial pathogenesis (Smith-Palmer et al., 2002). For example, Smith-Palmer 
and coworkers (2004) reported that sub-inhibitory concentrations of oils of cinnamon, bay, 
clove and thyme significantly decreased the production of enterotoxin A and α-toxin, two 
virulence factors in S aureus. The authors concluded that since the essentials oils did not 
directly inactivate or prevent export of α-toxin from the cells, their inhibitory activity could 
be at the transcriptional or translational level. Similarly, low concentrations of 
cinnamaldehyde were reported to inhibit quorum sensing (QS) or cell-density dependent 
regulation of gene expression in E. coli and biofilm synthesis in Vibrio spp. without 
inhibiting bacterial growth (Brackman et al., 2008). Amalaradjou et al (2011) demonstrated 
that  trans-cinnamaldehyde reduced the expression of several virulence genes essential for 
UPEC motility, host cell attachment and invasion. Thus, the ability of trans-cinnamaldehyde 
to inhibit bacteria  through multipronged mechanisms makes it a potential candidate for use 
as an antimicrobial agent for  controlling UTIs. 
2.1.6 Other herbs 
Essential oil extracted from Salvia officinalis (Garden sage; common sage) has been shown to 
be inhibitory against several uropathogens obtained from the urine samples of individuals 
with UTIs. Sage oil completely inhibited several pathogens, including Klebsiella, Enterobacter 
species, E. coli , Proteus mirabilis and Morganella morganii  (Pereira et al., 2004). Barosma 
betulina (bachu) is another herb which has been used in the treatment of urinary tract 
infection, catarrhal cystitis and urethritis for a long time (Barnes et al., 2007). In vitro studies 
have demonstrated its antimicrobial effect against uropathogens (Mills and Bone, 2000). In 
addition to its antimicrobial effect,  bachu also has diuretic properties (Simpson, 1998).  
Several other herbs that are used for the treatment of UTIs but lack scientific basis include 
Agrimonia eupatoria (agrimony), Althea officinalis (marshmallow), Apium graveolens (celery 
seed), Arctium lappa (burdock), Elymus repens (couchgrass), Hydrangea aborescens 
(hydrangea), Juniperus communis (juniper), Mentha piperita (peppermint), Taraxacum officinalis 
leaf (dandelion), Ulmus fulva (slippery elm) and Zea mays (corn silk). 
2.2 Dietary interventions 
Besides the use of antimicrobials, several nutrients have been used in the management, 
prevention and treatment of UTIs. These include vitamins, salts, and sugars. 
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2.2.1 Vitamins  
Ochoa et al (2007) investigated the efficacy of vitamin C for its effect on UTIs in pregnant 
women. The study consisted of 110 pregnant women who were divided into two groups. 
One group received a dose of 100 mg vitamin C daily while the other group was used as a 
control for a period of three months. Urine sample was collected from the subjects and 
evaluated for presence of uropathogens. The results  of this study revealed that the vitamin 
C  group had a significantly lower incidence of UTIs than the control group. Similarly, the 
use  of vitamin A in the management of UTIs in children was evaluated by Yilmaz et al 
(2007).  This study tested 24 children, 12 in the vitamin A group who received 200,000 IU of 
vitamin A, in addition to antimicrobial therapy for 10 days and 12 in the control group who 
just received the antimicrobial. The subjects were followed for one year and continued on 
antibiotic prophylaxis. It was observed that the children in the vitamin A group had a 
significantly lower incidence of UTIs than the control group.  
2.2.2 Citrate salts 
The purpose behind the use of citrate salts in the management of UTIs is to alkalinize the 
urine, since alkaline urine can provide significant benefit for UTI symptoms such as dysuria. 
In a study conducted by Spooner (1984), it was shown that intake of sodium citrate in 
women with UTI for a period of 48 hours significantly improved symptoms in 80 percent of 
the subjects with bacteriuria. In addition to improving symptoms like dysuria, alkalinity in 
the urine aids to provide an effective environment for certain antimicrobials such as uva ursi 
and berberine to function (Head, 2008). Potassium and sodium citrate have also been found 
to be effective against urinary candidiasis, a mold infection associated with the presence of 
indwelling catheters. Strassner and Friesen (1995), in a clinical study with hospitalized 
patients, demonstrated that oral intake of potassium-sodium-hydrogen-citrate for a period 
of two days to one month resulted in a significant increase in urinary pH and simultaneous 
disappearance of Candida in the urine. 
2.2.3 D- mannose 
Simple sugars like D-mannose prevent adherence of bacteria to uroepithelial cells. Ofek and 
Beachey (1978) identified a mannose-specific lectin on the surface of adherent strains of E. 
coli. Mannose functions as the primary bladder cell receptor site for UPEC to bind. Likewise, 
Hung et al (2002) reported that the first step in the adhesion of UPEC to the uroepithelial 
cells is the binding of FimH adhesin to the bladder epithelium via interaction with mannose 
moieties on the host cell surface. Thus the use of mannose or mannose analogs can help to 
block adhesion of E. coli to the bladder epithelium. 
Several studies have also investigated the efficacy of alpha-glycosides of mannose and D-
mannose in controlling UTIs (Firon et al., 1987; Schaeffer et al., 1984). An in vivo study 
conducted in mouse demonstrated that D-mannose not only blocked adhesion of E. coli to 
the urinary tract epithelium, but also prevented bacterial invasion and subsequent biofilm 
formation (Wellens et al., 2008). Growth of E. coli strains isolated from women with 
recurrent UTIs in the presence of D-mannose inhibited the adherence of E. coli by 42% 
(Schaffer et al., 1984). Similarly in a study of urinary tract epithelial cells collected from 
voided urine of healthy women, use of a 2.5% solution of D-mannose, D- mannitol or alpha-
methyl-D-mannoside completely inhibited E. coli adherence to the uroepithelium. However, 
when a similar concentration of D-lyxose, D-arabinose, D-fructose and D-glyceraldehyde 
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were used, only a partial inhibition of bacterial adhesion was noticed. Additionally, the use 
of lower concentrations (0.1-1.0%) of mannose, mannitol and mannoside also resulted in a 
partial inhibition of bacterial adhesion to urinary tract epithelial cells (Schaffer et al., 1980).  
In addition to the use of naturally existing mannose residues and its derivatives in the 
control of UTIs, Klein et al (2010) synthesized and evaluated the efficacy of several 
mannosides in blocking bacterial-host interaction. Among the different mannosides 
developed and evaluated using a mouse UTI model, para substituted biphenyl derivative of 
D-mannose was found to be the most effective in controlling UTIs. Following oral 
administration of this mannoside, bacterial numbers were reduced by 2 orders and 4 orders 
of magnitude in the urine and bladder, respectively. This FimH antagonist thus provides an 
alternative approach with a new class of orally available antimicrobials for effective 
treatment of UTIs. 
2.3 Probiotics 
Probiotics are live organisms which when administered in adequate amounts confer a health 
benefit on the host (FAO/WHO, 2001).  The rationale for the use of probiotics is based on 
the gastrointestinal and genitourinary regulatory role played by the commensal microflora, 
and the need for restoration of this microbial ecosystem after an imbalance or infection 
(Barrons and Tassone, 2008). For use as a probiotic in controlling UTIs, the candidate culture 
must exhibit adequate antibacterial properties. For example, an important attribute of an 
ideal probiotic culture such as lactobacilli is the ability to maintain a low pH ≤ 4.5, where the 
acidic environment provides lactobacilli a favorable environment to multiply and produce 
additional antibacterial molecules, including bacteriocin and hydrogen peroxide 
(Aroutcheva et al., 2001). In a study investigating the defense factors against infection in 22 
lactobacilli strains isolated from healthy human vaginal ecosystems, moderate to high 
production of hydrogen peroxide and bacteriocin was observed in 82% and 68% of the 
strains (Aroutcheva et al., 2001).  
Besides their ability to produce acid, hydrogen peroxide and bacteriocins, lactobacilli may 
also offer protection against UTIs through the production of biosurfactants. Biosurfactants 
inhibit growth of uropathogens by inhibiting the adhesion of these pathogens to the 
uroepithelium (Velraeds et al., 1996). A study conducted using 15 strains of lactobacilli 
showed that the strains produced varying amounts of biosurfactants providing up to 82% 
inhibition of Enterococcus fecalis adhesion to a glass surface (Velraeds et al., 1996). Moreover, 
lactobacilli co-aggregate with uropathogens to block their adhesion and/or displace 
previously adherent uropathogens from the urinary tract. This co-aggregation can create a 
microenvironment in which the inhibitory substances produced by the lactobacilli can 
concentrate on the pathogens and inhibit them (Mastromarino et al., 2002). 
Osset et al (2001) conducted an in vitro study in which the antimicrobial ability of 15 
Lactobacillus species against pathogens was investigated. Lactobacillus crispatus was found to 
be the species that demonstrated the strongest ability to block pathogen adhesion. Another 
in vitro study examined the antagonistic effect of five probiotic species against six 
pathogenic bacteria. The results revealed that a pyelonephritic E. coli strain was sensitive to 
Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb 12 and Bifidobacterium longus 46 (Hutt et 
al., 2006).  
Several clinical studies have investigated the effect of probiotic suppositories for the 
prevention of UTIs. Reid et al (1992) investigated the effect of probiotic lactobacill in 
controlling infection in women with acute UTIs (Reid et al., 1995). These patients were 
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treated with antibiotics for three days and recurrence occurred in 41% of the patients. These 
individuals were randomly assigned to Lactobacillus suppositories or placebo suppositories 
twice weekly for two weeks, then once a month for the next two months. Recurrence was 21 
percent in the Lactobacillus group compared to 47% in the placebo group.  The same group 
of researchers conducted a follow-up study comparing the effects of suppositories 
containing the Lactobacillus species with suppositories containing Lactobacillus growth 
factor. The subjects were administered with either one of the suppositories once weekly for 
12 months.  At the end of the 12 months, both the groups exhibited a 73% reduction in the 
incidence of UTIs (Reid et al., 1995). 
Studies were also conducted to evaluate the efficacy of oral probiotics in controlling UTIs. In 
order for an oral probiotic to be effective, it must be able to colonize the intestinal and/or 
urogenital region. L. rhamonosus GR-1 and L. fermentum RC-14 were administered twice 
daily for 14 days and the bacterial recovery from the vaginal tissue was monitored (Reid et 
al., 2001). It was observed that the vaginal epithelium was colonized with lactobacilli within 
one week of the oral administration (Reid et al., 2001). Similarly studies in pediatric 
populations revealed that administration of L. rhamnosus GG orally for 50 days resulted in a 
reduction in UTI incidence rate compared to the placebo group (Dani et al., 2002). Taken 
together, results from these aforementioned studies suggest the potential benefit of  
probiotics in controlling UTIs.  
2.4 Hormone therapy 
In postmenopausal women, hormone waning results in thinning of the vaginal and urethral 
mucosa, disruption of the normal vaginal flora and an increased risk for UTIs (Head, 2008). 
Therefore administration of estrogen in such patients has been reported to  reduce UTIs. A 
randomized study including postmenopausal women evaluated the effect of intravaginally 
administered estriol in reducing UTIs. The results of this study showed a significant 
reduction in the incidence of UTIs compared to the placebo group. It was also observed that 
Lactobacilli that were absent in the vaginal cultures of subjects at the beginning of the trial 
reappeared in 61 percent of the estriol group (Raz and Stamm, 1993). 
2.5 Vaccines 
As with other infectious diseases, UTIs can also be controlled using vaccines. Wieser et 
al.(2010) reported that an ideal vaccine target against uropathogens should be (i) exposed on 
the bacterial surface and (ii) widely distributed among clinical isolates but not among 
commensal strains of the gut flora,  (iii) possess epitopes that are conserved across diverse 
strains, and (iv) elicit a protective immune response. Additional desirable characteristics of 
an effective vaccine target include increased expression at the site of infection and a role in 
the pathogenesis of disease (Wieser et al., 2010).  
Several studies have investigated the use of potential antigens as targets for vaccine 
development against UPEC. Initial studies for vaccine candidates consisted of single target 
protein or whole cells. Langermann et al (1997) evaluated the use of an adhesion based 
vaccine targeting the FimH protein on the surface of UPEC. Immunization with FimH 
reduced in vivo bacterial colonization of the bladder mucosa by more than 99 percent in a 
murine cystitis model, and immunoglobulin G to FimH was detected in the urinary samples 
from protected mice. Additionally, passive systemic administration of immune sera to FimH 
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also resulted in reduced bladder colonization by UPEC. A similar study by Li et al (2004) 
developed an intranasal vaccine against Proteus mirabilis infections in the urinary tract. The 
mice were vaccinated with formalin-killed bacteria or purified mannose-resistant Proteus-
like fimbriae (MR/P), a surface antigen expressed by P. mirabilis during UTI. Four different 
routes of administration, including subcutaneous, intradermal, intranasal and trans urethral 
were evaluated in this study, where intranasal administration of MR/P elicited the most 
protective immune response against P. mirabilis UTI. 
Alteri et al (2009) investigated the use of six novel vaccine candidates against UPEC. These 
candidates were indentified using bioinformatics, functional genomics, transcriptomic and 
proteomic analyses. All the six proteins  belonged to the class of outer membrane iron 
receptors that are upregulated in an iron restricted environment. Intranasal administration 
of these antigens in mice elicited both systemic and mucosal immune responses that 
included the production of antigen-specific IgM, IgG and IgA antibodies, cytokine responses 
and protection against UTI in the mouse model (Alteri et al., 2009). A similar study was also 
conducted by Wieser et al (2010), where they evaluated the use of a subunit vaccine against 
extra intestinal E. coli. Using a novel approach of computer-aided design, two completely 
artificial genes were created, both encoding eight peptide domains derived from these extra 
intestinal E. coli proteins. In mice, the vaccine was highly immunogenic, eliciting both strong 
humoral and cellular immune responses. Nasal application of the vaccine resulted in high 
secretory immunoglobulin A (sIgA) production, which was detectable on the mucosal 
surface of the urogenital tract. Finally, it bestowed protection, as shown by a significant 
reduction of bacterial load in a mouse model of extra intestinal E. coli peritonitis.  
Besides the use of immunogenic antigens as vaccines, immunotherapy for UTIs can also be 
accomplished using immunomodulants. A study carried by Krcmery et al (2010) 
investigated the efficacy of two immunomodulatory agents (Urovaxom and luivac) for the 
management of recurrent UTIs in women over a 12 month period. The results indicated that 
a combined treatment using immunotherapy and chemoprophylaxis significantly reduced 
the occurrences of UTI relapses in these women.  
3. Conclusion 
Infections of the genitourinary tract are common occurrences in individuals especially in 
young women, during pregnancy and in post menopausal women. The conventional use of 
antibiotics in the prevention and treatment of acute and chronic recurring infections 
contribute to gut and vaginal dysbiosis and bacterial antibiotic resistance. In an attempt to 
control the increasing trends in infections with antibiotic resistant uropathogens, there is a 
renewed interest in the use of non-antibiotic based intervention strategies against UTIs. 
Several studies have investigated the use of natural substances in the prevention and 
treatment of UTIs. Nutrients and botanicals such as cranberry, berberine, cinnamaldehyde, 
probiotics and vaccines have demonstrated the greatest effectiveness. While most clinical 
research has evaluated the antimicrobial potential of these natural substances, their 
mechanism of action and the clinical experience of health care practitioners are critical for 
evaluating  their effectiveness (Head, 2008). Use of these alternatives in the control of UTIs 
would help to circumvent dysbiosis and microbial drug resistance induced by the repeated 
use of antibiotics. 
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